Spectrum Pharmaceuticals EBIT

Spectrum Pharmaceuticals (SPPI) currently reports a EBIT of $-64M as of March 2023. That compares with $-130M in the prior-year period — up 50.4% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Spectrum Pharmaceuticals's EBIT history and peer comparisons.

Spectrum Pharmaceuticals's EBIT increased from $-130M to $-64M — a 50.4% year-over-year increase (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Spectrum Pharmaceuticals's EBIT of $-64M is lower than the Healthcare sector average of $110B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Spectrum Pharmaceuticals reported $-64M in EBIT as of March 2023. That compares with $-130M in the prior-year period — up 50.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-64M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Spectrum Pharmaceuticals, and consider following SPPI for alerts when major investors trade the stock.